Muscle Protein Synthesis Following Protein Administration in Critical Illness
Date
2022
Authors
Chapple, L.-A.S.
Kouw, I.W.K.
Summers, M.J.
Weinel, L.M.
Gluck, S.
Raith, E.
Slobodian, P.
Soenen, S.
Deane, A.M.
van Loon, L.J.C.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
American Journal of Respiratory and Critical Care Medicine, 2022; 206(6):740-749
Statement of Responsibility
Lee-anne S. Chapple, Imre W. K. Kouw, Matthew J. Summers, Luke M. Weinel, Samuel Gluck, Eamon Raith, Peter Slobodian, Stijn Soenen, Adam M. Deane, Luc J. C. van Loon, and Marianne J. Chapman
Conference Name
Abstract
Rationale: Dietary protein may attenuate the muscle atrophy experienced by patients in the ICU, yet protein handling is poorly understood. Objectives: To quantify protein digestion and amino acid absorption and fasting and postprandial myofibrillar protein synthesis during critical illness. Methods: Fifteen mechanically ventilated adults (12 male; aged 506 17 yr; body mass index, 276 5 kg m22 ) and 10 healthy control subjects (6 male; 546 23 yr; body mass index, 276 4 kg m22 ) received a primed intravenous L-[ring-2 H5]-phenylalanine, L-[3,5-2 H2]-tyrosine, and L-[1-13C]-leucine infusion over 9.5 hours and a duodenal bolus of intrinsically labeled (L-[1-13C]-phenylalanine and L-[1-13C]-leucine) intact milk protein (20 g protein) over 60 minutes. Arterial blood and muscle samples were taken at baseline (fasting) and for 6 hours following duodenal protein administration. Data are mean6 SD, analyzed with two-way repeated measures ANOVA and independent samplest test. Measurements and Main Results: Fasting myofibrillar protein synthesis rates did not differ between ICU patients and healthy control subjects (0.0236 0.013% h21 vs. 0.0346 0.016% h21 ; P= 0.077). After protein administration, plasma amino acid availability did not differ between groups (ICU patients, 54.26 9.1%, vs. healthy control subjects, 61.86 13.1%; P= 0.12), and myofibrillar protein synthesis rates increased in both groups (0.0286 0.010% h21 vs. 0.0436 0.018% h21 ; main time effect P= 0.046; P-interaction = 0.584) with lower rates in ICU patients than in healthy control subjects (main group effect P= 0.001). Incorporation of protein-derived phenylalanine into myofibrillar protein was 60% lower in ICU patients (0.0076 0.007 mol percent excess vs. 0.0176 0.009 mol percent excess; P= 0.007). Conclusions: The capacity for critically ill patients to use ingested protein for muscle protein synthesis is markedly blunted despite relatively normal protein digestion and amino acid absorption.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2022 by the American Thoracic Society.